U.S. Medical Equipment Stock News

In the second quarter of 2026, Biogen Inc. reported revenue of US$2,736.0 million, up from US$2,645.5 million a year earlier, while net income fell to US$97.5 million and diluted earnings per share from continuing operations declined to US$0.66 from US$4.33. Despite higher sales and revenue, Biogen’s earnings compressed significantly, even as its newer therapies outpaced its legacy multiple sclerosis portfolio and the Apellis acquisition expanded its growth product lineup. We’ll now examine...

TOMS Capital’s no confidence campaign against Voya Financial (VOYA) has moved into a new phase, with a definitive proxy filing and an open letter challenging the board’s decisions, recent execution, and approach to potential third party interest. See our latest analysis for Voya Financial. At a share price of US$101.40, Voya Financial has delivered a 26.54% 90 day share price return and a 46.36% 1 year total shareholder return. This suggests recent momentum has been strong despite the fresh...

D.R. Horton stock has delivered a 62.8% gain over the past five years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples currently point to the shares trading below what those frameworks suggest as fair. Over the last five years, D.R. Horton has returned 62.8%, which means long term holders have already seen solid value creation even before considering today’s valuation signals. Market expectations for future housing demand and construction activity can...

ANI Pharmaceuticals just took a 5.3% hit in a single session, yet the earnings story looks more like growing pains than a broken thesis. You have a stock that came into the print soft over the past month, then sold off again right after reporting adjusted earnings per share of US$2.21 on revenue of US$266.0m. The real swing factor is profit quality. Investors appear to be wrestling with how much of the recent profitability and trailing US$259.6m of adjusted EBITDA reflects repeatable rare...

Embecta entered this quarter wearing the label of a deeply discounted diabetes device stock, with a single digit P/E and significant balance sheet questions. The market lifted the share price 26% to US$4.42 in the first session after earnings. The move reflects one headline takeaway: the business reported a sharp rebound in both revenue and profit, with Q3 sales of US$271.7m and net income of US$21.1m after a loss in Q2. For a company under pressure over debt and cash generation, that...

How PayPal's Latest Earnings Set the Stage for Investors PayPal Holdings (PYPL) just reported second quarter 2026 results, with sales of US$8.68b and net income of US$1.10b, giving investors a mixed update on growth and profitability. Sales for the first half of 2026 reached US$17.04b, while net income for the same period came in at US$2.22b. Earnings per share from continuing operations were lower than a year ago on both a basic and diluted basis. At the same time, PayPal Holdings (PYPL)...

In late July 2026, Laureate Education, Inc. reported second-quarter sales of US$615.86 million and net income of US$137.1 million, alongside higher first-half earnings and an updated full-year 2026 revenue outlook of US$1.92 billion to US$1.93 billion, implying 13% as-reported growth. At the same time, Laureate expanded its share repurchase effort, having already bought back 13,863,000 shares for US$399.61 million and adding a further US$250 million authorization, highlighting management’s...

Under Armour stock fell about 4.5% to US$6.11 in the first trading session after its Q1 2027 report, adding fresh pressure to an already weak one month stretch. At first glance the reaction looks harsh for a company that just posted a small profit and stronger than expected adjusted operating income. The real headline is not the quarter. It is the decision to cut full year revenue guidance to a mid single digit decline while still holding the US$140 million to US$160 million adjusted...

Praxis Precision Medicines (NasdaqGS: PRAX) reported new clinical and regulatory milestones across its central nervous system pipeline, including progress on several drug candidates. The company received FDA Breakthrough Therapy designation for Elsunersen, its investigational treatment for neurological disorders. Praxis expanded its CNS program through collaborations and licensing agreements with partners including RogCon Inc. and Ionis Pharmaceuticals. This kind of pipeline and partnership...

Century Aluminum stock has delivered a very large 3 year gain, yet it still screens as undervalued on Simply Wall St’s valuation checks. This sets up a clear question about how much upside may be left in the current price of US$51.23. Over the past 3 years the share price has risen by a very large amount, which puts more focus on whether recent returns can be supported by fundamentals. The completion of production restarts at Mt. Holly and Grundartangi can support revenue and earnings...

Tariff power that stretches up to 100% on key Russian energy importers puts trade relationships, inflation, and company cost structures back in the spotlight. That kind of policy shock can quickly separate potential winners from stocks that may struggle. This article walks through three U.S. utilities and infrastructure stocks that appear positioned on the positive side of this story and explains why their businesses could matter for your watchlist now. The stocks covered below are just a...

BridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, with the stock closing at $84.48 on 6 August 2026. Investors are weighing this level against the company’s longer term return profile. See our latest analysis for BridgeBio Pharma. The latest move in BridgeBio Pharma’s share price builds on a 30.61% 90 day share price return and an 81.37% 1 year total shareholder return. However, the 30 day share price return of 1.64% shows some cooling in the very short...

Zillow Group (NasdaqGS:ZG) has announced a series of executive leadership changes, including a new Chief Legal and Policy Officer. Cassandra Knight, previously Vice President, Litigation and Discovery at Google, has been appointed Chief Legal and Policy Officer at Zillow Group. Jeremy Hofmann's responsibilities have been expanded to COO and CFO, with additional leadership promotions across the company. These leadership moves at Zillow Group highlight a wider shift in how real estate and...

UWM Holdings Corporation recently reported a Q2 2026 net loss of US$80.59 million, reversing from net income of US$22.91 million a year earlier, and filed an omnibus shelf registration covering multiple securities classes, while also suspending its dividend and raising new capital amid a pressured mortgage market. This combination of weaker profitability, dividend suspension, and added capital-raising flexibility signals a renewed focus on balance sheet strength and financial resilience for...

After a strong three-year run that has seen Gates Industrial stock return about 139%, the current share price now sits against an intrinsic value estimate that still points to upside, while the broader valuation checks paint more of a mixed picture. The roughly 139% return over three years puts Gates Industrial in clear outperformer territory, so the key issue now is whether the current price still leaves room for further value. Recent earnings strength and upgraded expectations can support...

Compass, Inc. recently reported past second-quarter 2026 results showing sales of US$4.31 billion and net income of US$92 million, alongside significantly higher revenue and earnings for the first half of the year compared with the prior period. The swing from a net loss to a net profit over the first six months of 2026, together with higher basic and diluted earnings per share, highlights a meaningful improvement in Compass’s profitability profile. We’ll now examine how Compass’s sharp...

Tredegar stock jumped 14.7% to US$8.89 following the earnings release, indicating that traders liked what they saw on the surface. The more important consideration for shareholders is not today’s price move. The key shift is that Tredegar now reports trailing twelve month earnings from continuing operations of US$32.7m and basic EPS of US$0.94 after earlier losses. That return to profit comes alongside a five-year earnings decline of about 22.3% a year. The rest of this report examines...

Mobility Global dropped almost 5% to US$19.70 after its first post spin earnings, yet the core numbers look more measured than the price reaction suggests. The market is fixating on valuation strain, not the operating story. Revenue reached US$468m for the quarter with an adjusted EBITDA margin above 40%, while the stock still trades on a P/E of 28.3x, richer than both its industry and peer averages. Today’s selloff is really a verdict on how much investors are willing to pay for this...

Steris walked into this earnings season with a premium P/E tag and a reputation as a steady medical equipment compounder, yet the stock only moved about 2.5% higher to US$237.47 after the print. The market reaction looked calm compared with what the numbers actually signaled. Revenue reached US$1,492.7m and net income came in at US$200.1m for Q1 FY2027, while earnings per share hit US$2.05. The real story sits in how those profits stack up against Steris’s richer valuation and recent margin...

Hawaiian Electric Industries came into this report with a stock that has been grinding lower for months, down about 11% over the past quarter, and the immediate reaction is muted. The share price slipped less than 1% to around US$12.40, which indicates that the market is still cautious even after a headline quarter that showed US$123.2 million of net income and US$0.71 in earnings per share. The catch is that much of that profit came from a large non cash accounting benefit tied to Maui...

Sabine Royalty Trust walked into this earnings season with a mixed reputation. The stock carried a rich P/E of 14.7x versus lower industry and peer averages, yet screens as trading well below one prominent fair value estimate. After the Q2 release, the market shrugged off the recent 90 day share price drift and pushed the units up about 2%. The headline is straightforward. Sabine Royalty Trust reported a strong quarter for a royalty vehicle, with Q2 net income of about US$20.8 million and...

Pfizer’s sharp drop in Covid vaccine revenues and rising short interest have put big pharma under a harsh spotlight, which pulls the wider biotechnology sector into focus. When a heavyweight like Pfizer faces questions over debt, dividends and pipeline depth, other large biotech stocks can suddenly look more interesting or more exposed. This article walks through 3 stocks from our Biotechnology Sector screener that appear positively linked to this news backdrop and explains why each might...

Papa John’s International, Inc. reported second-quarter 2026 results showing revenue of US$482.4 million and net income of US$8.53 million, and also announced a suspension of its quarterly dividend from the third quarter of 2026 onward. Alongside softer earnings, the company reshaped its leadership team with new global marketing and development heads as part of a broader transformation focused on international growth and brand evolution. We’ll now examine how the dividend suspension, aimed...

Investors came into this Take-Two Interactive Software print already paying up for the story, and the stock just added another 6% in a single session. The move reflects relief more than surprise. Q1 fiscal 2027 delivered about US$1.53b in revenue and a narrower loss of roughly US$34.1m, while net bookings of US$1.39b landed slightly ahead of guidance. For a company long treated as a high multiple bet on Grand Theft Auto VI and live services, this quarter is focused on whether shrinking...